Current Edition

DLBCL

Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL

Immunovaccine Inc., a clinical stage immuno-oncology company, today announced that the first patient has been treated in a Phase 2 Study combining DPX-Survivac with Low …

Continue Reading →